{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:25:40Z","timestamp":1791419140565,"version":"4.3.3"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005039","name":"Leids Universitair Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006209","name":"Radboud Universitair Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006209","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007453","name":"Nederlandse Vereniging voor Trombose en Hemostase","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003061","name":"Erasmus Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jtha.2022.12.027","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T10:24:29Z","timestamp":1674642269000},"page":"413-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["The ethics of gene therapy for hemophilia: a narrative review"],"prefix":"10.1016","volume":"21","author":[{"given":"Lieke","family":"Baas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieke","family":"van der Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien S.","family":"van Hoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelien L.","family":"Bredenoord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2022.12.027_bib1","first-page":"1773","article-title":"The hemophilias - from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"Med Prog"},{"key":"10.1016\/j.jtha.2022.12.027_bib2","doi-asserted-by":"crossref","unstructured":"Gura T. After a setback, gene therapy progresses. Gingerly. Science 2001;291:1692\u20137. https:\/\/doi.org\/10.1126\/SCIENCE.291.5509.1692\/ASSET\/C91F1A99-462E-4F73-9EEB-75E30E463989\/ASSETS\/GRAPHIC\/1692-5.GIF.","DOI":"10.1126\/science.291.5509.1692"},{"key":"10.1016\/j.jtha.2022.12.027_bib4","first-page":"1","article-title":"The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing","volume":"6736","author":"Mancuso","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2022.12.027_bib5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrg2317","article-title":"The ethics of human gene transfer","volume":"9","author":"Kimmelman","year":"2008","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jtha.2022.12.027_bib6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1046\/j.1365-2516.2002.00615.x","article-title":"Progress in haemophilic care: ethical issues","volume":"8","author":"Berntorp","year":"2002","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.027_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2516.2003.00725.x","article-title":"Gene therapy ethics and haemophilia: an inevitable therapeutic future?","volume":"9","author":"DiMichele","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.027_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2516.2007.01567.x","article-title":"Staunch protections: the ethics of haemophilia gene transfer research","volume":"14","author":"Kimmelman","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.027_bib9","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41591-019-0511-6","article-title":"Ethical development of stem-cell-based interventions","volume":"25","author":"MacPherson","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2022.12.027_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12910-020-00524-z","article-title":"Ethics parallel research: an approach\u00a0for (early) ethical guidance of biomedical innovation","volume":"21","author":"Jongsma","year":"2020","journal-title":"BMC Med Ethics"},{"key":"10.1016\/j.jtha.2022.12.027_bib11","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in\u00a0vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2022.12.027_bib12","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2022.12.027_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/hae.13673","article-title":"Members of the WFH Gene Therapy Round Table\u00a0Program Committee and Organizing Committee. The 1st WFH Gene Therapy Round Table: understanding the landscape and challenges of gene therapy for haemophilia around the world","volume":"25","author":"Pierce","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.027_bib14","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd.2018.70","article-title":"Advances and innovations in haemophilia treatment","volume":"17","author":"Peters","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jtha.2022.12.027_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12695","article-title":"Impact of novel hemophilia therapies around the world","volume":"6","author":"Ozelo","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.027_bib16","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1538-7836.2005.01412.x","article-title":"Gene therapy for hemophilia?","volume":"3","author":"Brettler","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.027_bib17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1046\/j.1365-2516.2002.00646.x","article-title":"Gene therapy: reality or myth for the global bleeding disorders community?","volume":"8","author":"Kelley","year":"2002","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.027_bib18","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/j.1538-7836.2005.01409.x","article-title":"Gene therapy for hemophilia is both desirable and achievable in the near future","volume":"3","author":"Tuddenham","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.027_bib19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1365-2516.2008.01738.x","article-title":"Ethical considerations in clinical investigation: exploring relevance in haemophilia research","volume":"14","author":"DiMichele","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.027_bib20","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1365-2516.2008.01660.x","article-title":"Walk a mile in the moccasins of people with haemophilia","volume":"14","author":"Ponder","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.027_bib21","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2516.2001.00533.x","article-title":"Decisions and dilemmas: resolving ethical, medical and economic issues facing haemophilia care","volume":"7","author":"Mannucci","year":"2001","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.027_bib22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.7861\/clinmedicine.4-1-54","article-title":"Gene therapy trials in the UK: is haemophilia a suitable \u201cmodel\u201d","volume":"4","year":"2004","journal-title":"Clin Med"},{"key":"10.1016\/j.jtha.2022.12.027_bib23","doi-asserted-by":"crossref","unstructured":"Ozelo MC, Mahlangu J, Pasi KJ, Giermasz A, Leavitt AD, Laffan M, Symington E, Quon DV, Wang JD, Peerlinck K, Pipe SW, Madan B, Key NS, Pierce GF, O'Mahony B, Kaczmarek R, Henshaw J, Lawal A, Jayaram K, Huang M, et\u00a0al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med 2022;386:1013\u20131025. https:\/\/doi.org\/10.1056\/NEJMOA2113708\/SUPPL_FILE\/NEJMOA2113708_PROTOCOL.PDF.","DOI":"10.1056\/NEJMoa2113708"},{"key":"10.1016\/j.jtha.2022.12.027_bib24","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.2019003777","article-title":"Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues","volume":"138","author":"Leebeek","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.027_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/hae.14530","article-title":"Gene therapy \u2013 are we ready now?","volume":"28","author":"Kaczmarek","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.027_bib26","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1089\/hum.2017.150","article-title":"Unraveling the complex story of immune responses to AAV vectors trial after trial","volume":"28","author":"Vandamme","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2022.12.027_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/hae.13510","article-title":"Emerging therapies for haemophilia\u2014global perspective","volume":"24","author":"Mahlangu","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.027_bib28","article-title":"The evolving landscape of gene therapy for congenital haemophilia: an unprecedented, problematic but promising opportunity for worldwide clinical studies","volume":"46","author":"Spadarella","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2022.12.027_bib29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/hae.13971","article-title":"Members of the WFH Gene Therapy Round Table\u00a0Program Organizing Committee. Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round Table","volume":"26","author":"Pierce","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.027_bib30","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2516.2006.01258.x","article-title":"Ethical issues in haemophilia","volume":"12","author":"DiMichele","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.027_bib31","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1517\/14712598.2015.1029451","article-title":"Biological therapies for inherited diseases: social and bioethical considerations. Hemophilia as an example","volume":"15","author":"Liras","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jtha.2022.12.027_bib32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1055\/s-2004-825637","article-title":"Hemophilia gene transfer: comparison with conventional protein replacement therapy","volume":"30","author":"Ragni","year":"2004","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2022.12.027_bib33","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1016\/j.ymthe.2021.10.025","article-title":"Eliminating Panglossian thinking in development of AAV therapeutics","volume":"29","author":"Kaczmarek","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2022.12.027_bib34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13023-022-02256-2","article-title":"The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the Exigency study","volume":"17","author":"Fletcher","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jtha.2022.12.027_bib35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/hae.14023","article-title":"Uncertainty in an era of transformative therapy for haemophilia: addressing the unknowns","volume":"27","author":"Pierce","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.027_bib36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/hae.13489","article-title":"Past, present and future of haemophilia gene therapy: from vectors and transgenes to known and unknown outcomes","volume":"24","author":"Pierce","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.027_bib37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/bmj.330.7482.79","article-title":"Recent developments in gene transfer: risk and ethics","volume":"330","author":"Kimmelman","year":"2005","journal-title":"Br Med J"},{"key":"10.1016\/j.jtha.2022.12.027_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/sj.mt.6300316","article-title":"Stable ethics: enrolling non-treatment-refractory volunteers in novel gene transfer trials","volume":"15","author":"Kimmelman","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2022.12.027_bib39","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1365-2516.2004.00999.x","article-title":"What is a cure and how do we get there?","volume":"10","author":"Skinner","year":"2004","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.027_bib40","article-title":"Improving patient informed consent for haemophilia gene therapy: the case for change","volume":"2","author":"Woollard","year":"2021","journal-title":"Clin Med Surg"},{"key":"10.1016\/j.jtha.2022.12.027_bib41","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/hae.14188","article-title":"Parental perspectives on gene therapy for children with haemophilia: the Exigency study","volume":"27","author":"Khair","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.027_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14378","article-title":"An exploration of why men with severe haemophilia might not want gene therapy: the Exigency study","volume":"27","author":"Fletcher","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.027_bib43","article-title":"Why I don\u2019t want to cure my hemophilia with gene therapy","author":"Zhang","year":"2018","journal-title":"Atlantic"},{"key":"10.1016\/j.jtha.2022.12.027_bib44","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/medethics-2011-100044","article-title":"The burden of normality: from \u201cchronically ill\u201d to \u201csymptom free.\u201d New ethical challenges for deep brain stimulation postoperative treatment","volume":"38","author":"Gilbert","year":"2012","journal-title":"J\u00a0Med Ethics"},{"key":"10.1016\/j.jtha.2022.12.027_bib45","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/jnnp.70.5.649","article-title":"The \u201cburden of normality\u201d: concepts of adjustment after surgery for seizures","volume":"70","author":"Wilson","year":"2001","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jtha.2022.12.027_bib46","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/1467-9566.ep11339939","article-title":"Chronic illness as biographical disruption","volume":"4","author":"Bury","year":"1982","journal-title":"Sociol Health Illn"},{"key":"10.1016\/j.jtha.2022.12.027_bib47","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10880-018-9552-0","article-title":"Illness identity in adults with a chronic illness","volume":"25","author":"Oris","year":"2018","journal-title":"J\u00a0Clin Psychol Med Settings"},{"key":"10.1016\/j.jtha.2022.12.027_bib48","first-page":"5","article-title":"Living with a \u201chemophilia-free mind\u201d \u2013 the new ambition of hemophilia care?","author":"Krumb","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.027_bib49","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/hae.14587","article-title":"The legacy of haemophilia: memories and reflections from three survivors","volume":"28","author":"Farrugia","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.027_bib50","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/j.1528-1167.2009.02392.x","article-title":"Profiles of psychosocial outcome after epilepsy surgery: the role of personality","volume":"51","author":"Wilson","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.jtha.2022.12.027_bib51","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1086\/JCE201021206","article-title":"Philosophical reflections on narrative and deep brain stimulation","volume":"21","author":"Schechtman","year":"2010","journal-title":"J\u00a0Clin Ethics"},{"key":"10.1016\/j.jtha.2022.12.027_bib52","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s12152-011-9137-1","article-title":"\u201cI Am Who I Am\u201d: on the perceived threats to personal identity from deep brain stimulation","volume":"6","author":"Baylis","year":"2013","journal-title":"Neuroethics"},{"key":"10.1016\/j.jtha.2022.12.027_bib53","doi-asserted-by":"crossref","first-page":"E679","DOI":"10.1097\/HS9.0000000000000679","article-title":"Modeling benefits, costs, and affordability of a novel gene therapy in hemophilia A","volume":"6","author":"Ten Ham","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.jtha.2022.12.027_bib54","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood.2021010864","article-title":"The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective","volume":"138","author":"Bolous","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.027_bib55","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/bloodadvances.2018021345","article-title":"Gene therapy in hemophilia A: a cost-effectiveness analysis","volume":"2","author":"Machin","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2022.12.027_bib56","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.transci.2019.08.012","article-title":"Gene therapy for hemophilia: progress to date and challenges moving forward","volume":"58","author":"Gollomp","year":"2019","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jtha.2022.12.027_bib57","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/hae.14425","article-title":"Alternative payment models for durable and potentially curative therapies: the case of gene therapy for haemophilia A","volume":"28","author":"Goodman","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.027_bib58","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/hae.14218","article-title":"Reimbursing the value of gene therapy care in an era of uncertainty","volume":"27","author":"Noone","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.027_bib59","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jth.15182","article-title":"Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001\u20132018","volume":"19","author":"Hassan","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.027_bib60","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1136\/jme.2003.007138","article-title":"Ethical issues in funding orphan drug research and development","volume":"31","author":"Gericke","year":"2005","journal-title":"J\u00a0Med Ethics"},{"key":"10.1016\/j.jtha.2022.12.027_bib61","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/medethics-2021-107691","article-title":"Should rare diseases get special treatment?","volume":"48","author":"Magalhaes","year":"2022","journal-title":"J\u00a0Med Ethics"},{"key":"10.1016\/j.jtha.2022.12.027_bib63","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1\u20132 trial of AAVS3 gene therapy in patients with hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N\u00a0Engl J Med"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362219077X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362219077X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:37:49Z","timestamp":1761536269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362219077X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S153878362219077X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2022.12.027","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The ethics of gene therapy for hemophilia: a narrative review","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2022.12.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}